Saccharomyces cerevisiae CNCM I-3856

DIETARY_SUPPLEMENT3 trials

Sponsors

University of Nottingham, Lesaffre International

Conditions

Constipation-predominant Irritable Bowel SyndromeIrritable Bowel SyndromePost Infective Bowel Dysfunction

Unknown Phase

Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction

WithdrawnNCT00977587

University of NottinghamIrritable Bowel Syndrome, Post Infective Bowel Dysfunction

Start: 2011-01-31End: 2012-07-31Updated: 2017-06-20

Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel Syndrome

CompletedNCT01613456

Lesaffre InternationalIrritable Bowel Syndrome

Start: 2011-12-31End: 2013-06-30Updated: 2015-05-14

Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype

CompletedNCT03150212

Lesaffre InternationalConstipation-predominant Irritable Bowel Syndrome

Start: 2017-03-20End: 2019-05-09Updated: 2019-05-21

Related Papers

<i>Saccharomyces cerevisiae </i>I-3856 in irritable bowel syndrome with predominant constipation

World Journal of Gastroenterology2022-06-0823 citations

Randomized double blind placebo-controlled trial of<i>Saccharomyces cerevisiae</i>CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation

United European Gastroenterology Journal2015-08-2181 citations